Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q2 2025 · 10-Q
Revenue$0.00$0.00— vs Q2 2024 Net Income-$15.56K-$15.56KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Operating Income-$13,614N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
derived
ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d after period end